The different p53 effects suggest that there are different pathways for glioma tumorigenesis and point out the opportunity for designing more selective therapeutic strategies by taking advantage of the increased vulnerability of mutant p53 cells. This evidence concerns the gene TP53 and central nervous system cancer.